[ad_1]
WASHINGTON: A new way to help the body’s immune system overcome this deception and destroy cancer has been discovered by a researcher at the University of Missouri.
“Normally, the immune cells in your body are constantly on patrol to identify and destroy foreign entities in the body,” said Yves Chabu, assistant professor in the Division of Biological Sciences.
“Normal cells set up a ‘don’t eat me’ molecular flag that is recognized by immune cells, preventing the destruction of normal tissue. But some cancers have also developed the ability to mimic normal cells and produce this. “Donation” Therefore, the immune system does not recognize cancer as defective tissue and leaves it alone, which is bad news for the patient, ”Chabu added.
Immunotherapies are cancer drugs that essentially block the “don’t eat me” signal from cancer and allow the immune system to kill it.
Chabu, whose appointment is to the College of Arts and Sciences, said that while these immunotherapies work for certain types of cancers, prostate cancer is highly immunosuppressive, which means that the physical and molecular environments of cancer simply dominate. the body’s immune system.
But Chabu may have unlocked a solution with the help of a strain of bacteria over 50 years old.
“Cancers are different from one individual to another, even when they affect the same tissue. These interpersonal differences help determine whether a particular therapy will effectively kill the cancer and help the patient. The bacteria itself is genetically pliable. , so it can be genetically engineered to exceed patient-specific therapeutic limits, ”Chabu said.
“Imagine a patient whose cancer does not respond to traditional therapies and has no other treatment options. One can consider genetically modifying the bacteria so that it can unload therapies that specifically exploit the unique vulnerabilities of this cancer. and kill him, ”Chabu added.
In a previous study, scientists at the Cancer Research Center and the University of Missouri developed a genetically distinct, non-toxic strain of salmonella called CRC2631 to select and kill cancer cells.
CRC2631 was derived from another strain of salmonella that had been stored at room temperature for over half a century. Now scientists like Chabu are demonstrating the ability of CRC2631, which enthusiastically targets cancerous tumors, to be used to unleash the body’s immune system against prostate cancer.
“Because CRC2631 preferentially colonizes tumor cells, the effect is primarily localized to the tumor. The use of CRC2631 to design and deliver patient-friendly therapies predicts potential in precision medicine, or the ability to tailor treatment. to a specific patient, ”Chabu said.
Emphasizing the promise of personalized health care and the impact of large-scale interdisciplinary collaboration, the University of Missouri System’s NextGen Precision Health initiative brings together innovators from the system’s four research universities in pursuit of advancements in precision health that changes life.
It’s a collaborative effort to leverage the strengths of Mizzou and the entire UM system for a better future for Missouri health. An important part of the initiative is the construction of the new NextGen Precision Health building, which will expand collaboration between researchers, clinicians and industry leaders in a cutting-edge research facility.
[ad_2]
“Normally, the immune cells in your body are constantly on patrol to identify and destroy foreign entities in the body,” said Yves Chabu, assistant professor in the Division of Biological Sciences.
“Normal cells set up a ‘don’t eat me’ molecular flag that is recognized by immune cells, preventing the destruction of normal tissue. But some cancers have also developed the ability to mimic normal cells and produce this. “Donation” Therefore, the immune system does not recognize cancer as defective tissue and leaves it alone, which is bad news for the patient, ”Chabu added.
Immunotherapies are cancer drugs that essentially block the “don’t eat me” signal from cancer and allow the immune system to kill it.
Chabu, whose appointment is to the College of Arts and Sciences, said that while these immunotherapies work for certain types of cancers, prostate cancer is highly immunosuppressive, which means that the physical and molecular environments of cancer simply dominate. the body’s immune system.
But Chabu may have unlocked a solution with the help of a strain of bacteria over 50 years old.
“Cancers are different from one individual to another, even when they affect the same tissue. These interpersonal differences help determine whether a particular therapy will effectively kill the cancer and help the patient. The bacteria itself is genetically pliable. , so it can be genetically engineered to exceed patient-specific therapeutic limits, ”Chabu said.
“Imagine a patient whose cancer does not respond to traditional therapies and has no other treatment options. One can consider genetically modifying the bacteria so that it can unload therapies that specifically exploit the unique vulnerabilities of this cancer. and kill him, ”Chabu added.
In a previous study, scientists at the Cancer Research Center and the University of Missouri developed a genetically distinct, non-toxic strain of salmonella called CRC2631 to select and kill cancer cells.
CRC2631 was derived from another strain of salmonella that had been stored at room temperature for over half a century. Now scientists like Chabu are demonstrating the ability of CRC2631, which enthusiastically targets cancerous tumors, to be used to unleash the body’s immune system against prostate cancer.
“Because CRC2631 preferentially colonizes tumor cells, the effect is primarily localized to the tumor. The use of CRC2631 to design and deliver patient-friendly therapies predicts potential in precision medicine, or the ability to tailor treatment. to a specific patient, ”Chabu said.
Emphasizing the promise of personalized health care and the impact of large-scale interdisciplinary collaboration, the University of Missouri System’s NextGen Precision Health initiative brings together innovators from the system’s four research universities in pursuit of advancements in precision health that changes life.
It’s a collaborative effort to leverage the strengths of Mizzou and the entire UM system for a better future for Missouri health. An important part of the initiative is the construction of the new NextGen Precision Health building, which will expand collaboration between researchers, clinicians and industry leaders in a cutting-edge research facility.
Source link
